PMLS Virtual Series 2021 – Pharmacogenomics & Pharmacovigilance in Precision Medicine
On Demand Now Click Here
March 2, 2021
Gabriel Brooks, MD, MPH
Assistant Professor, Geisel School of Medicine, Dartmouth Institute of Health Policy and Clinical Practice
Gabriel Brooks, MD, MPH
Assistant Professor, Geisel School of Medicine, Dartmouth Institute of Health Policy and Clinical Practice
Gabriel Brooks is Assistant Professor of Medicine at the Geisel School of Medicine and The Dartmouth Institute of Health Policy and Clinical Practice. He is a health services researcher and a practicing medical oncologist at the Norris Cotton Cancer Center at Dartmouth. His research focuses on evaluating and improving the effectiveness, quality, and value of cancer care. A current area of interest in his research is developing strategies to advance the adoption and implementation of pharmacogenetic screening prior to cancer treatment with fluoropyrimidine chemotherapy. Clinically, Dr. Brooks specializes in the care of patients with gastrointestinal cancers.
Katherine Capps
Co-Founder and Executive Director, GTMRx
Katherine Capps
Co-founder and Executive Director, GTMRx
As executive director, Katherine Capps provides leadership by supporting GTMRx Institute’s mission and goals. She establishes and manages relationships with stakeholders across the health care spectrum. As a GTMR Institute Founding Board member, she works alongside other board members and collaboratively sets the strategy for the growth and activities of the organization.
Katie has a long history of collaboration in multi-stakeholder environments. As Health2 Resources’ founder and president, she and her team have helped more than 35 clients meet advocacy, policy, outreach, marketing and awareness goals. H2R was instrumental in the launch of the Patient-Centered Primary Care Collaborative, lending expertise for organizational development and marketing and communications.
She has served on the board of the Washington Adventist Health Foundation, the Institute for Health and Productivity Management (advisory board), the Healthcare Industry Access Initiative and Emmi Solutions. She has served on the board of the National Business Coalition on Health and its national advisory board, and on the NCQA purchaser committee. She writes on topics relating to quality, health care cost, market-based health care reform and the value of shared health information.
Amber B. Cipriani, PharmD, BCOP
Coordinator, Precision Medicine Pharmacy, University of North Carolina Medical Center; Clinical Assistant Professor, UNC Eshelman School of Pharmacy
Amber B. Cipriani, PharmD, BCOP
Coordinator, Precision Medicine Pharmacy, University of North Carolina Medical Center; Clinical Assistant Professor, UNC Eshelman School of Pharmacy
Amber Cipriani is a clinical pharmacist specialized in oncology care and pharmacogenomics. She currently serves as the Precision Medicine Pharmacy Coordinator at the University of North Carolina Medical Center where she works to implement initiatives that improve medication use and management through the utilization of technology, genetics, and clinical decision support tools. Dr. Cipriani’s position is a joint funded position with the UNC Eshelman School of Pharmacy, where she serves as a Clinical Assistant Professor delivering oncology pharmacotherapy content to professional PharmD students.
Dr. Cipriani worked in the pharmaceutical industry for a few years before her passion for patient care drove her to pursue her PharmD degree. She worked in the outpatient oncology clinics at UNC Health providing care for patients with melanoma, sarcoma, head/neck, and lung cancer prior to transitioning to her current role. She actively participates as a member of HOPA and serves as a liaison between HOPA and SITC.
Dr. Cipriani received a BA in Biochemistry and in Molecular,Cellular, and Developmental Biology from the University of Colorado in Boulder. She completed her PharmD degree at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences in Denver. She then pursued PGY1 Pharmacy Practice and PGY2 Hematology/Oncology training at the University of North Carolina. She is board certified in Oncology.
Jane Cheshire Gilbert, CPA
Director, Retiree Health Care, Teachers’ Retirement System, State of Kentucky
Jane Cheshire Gilbert, CPA
Director, Retiree Health Care, Teachers’ Retirement System, State of Kentucky
Jane Cheshire Gilbert is the director of retiree health care for the Teachers’ Retirement System of the State of Kentucky (TRS) and has served TRS retirees since April 2002. She manages two retiree health plans covering 48,000 retirees. She also serves as a leader in the areas of health insurance cost containment, project management, risk management and federal health care solutions.
Gilbert served in management and directorship positions for a Louisville Kentucky law firm and cost containment company, The Rawlings Company, from 1989 through 2002. Prior to that, she worked as an accountant for a national CPA firm.
Gilbert earned a bachelor’s degree in accounting from Bellarmine University in Louisville, Kentucky and is a certified public accountant and a certified government benefits administrator. She currently serves on the board of the State and Local Government Benefits Association and is a member of the Public Sector Healthcare Roundtable.
Kristine R. Crews, PharmD, FCCP, BCPS
Director, Translational Research Laboratory, St. Jude Children’s Research Hospital
Kristine R. Crews, PharmD, FCCP, BCPS
Director, Translational Research Laboratory, St. Jude Children’s Research Hospital
Kristine R. Crews is Translational Research Laboratory Director in the Pharmaceutical Sciences department at St. Jude Children’s Research Hospital and is Program Director of the first ASHP-Accredited PGY2 Residency in Clinical Pharmacogenomics. Dr. Crews earned both her B.S. in pharmacy and her Pharm.D. degrees from Rutgers University. She completed a pharmacy practice residency and a clinical pharmacokinetics specialty residency at the University of Kentucky Chandler Medical Center and completed a fellowship in clinical pharmacokinetics and pharmacodynamics at the University of North Carolina and Glaxo Wellcome, Inc. She is a Fellow of the American College of Clinical Pharmacy. Her research interests include pediatric oncology clinical trials and the clinical implementation of pharmacogenetics to individualize treatment regimens for children with cancer. She is a founding member of the Clinical Pharmacogenetics Implementation Consortium and serves as an author for CPIC guidelines.
Martin Dawes, PhD
Co-Founder and Chief Scientific Officer, GenXys Health Care Systems
Martin Dawes, PhD
Co-Founder and Chief Scientific Officer, GenXys Health Care Systems
Prof. Martin Dawes, with over 30 years of experience in research and clinical practice, is a globally renowned expert in pharmacogenetics in primary care. Following his Ph.D. at the University of Oxford, he helped develop a master’s program in Evidence-Based Health Care. He has directed the UK Centre for Evidence-Based Medicine in Oxford and was the head of family practice at McGill University and the University of British Columbia.
In 2014, he co-founded GenXys Health Care Systems, a Vancouver-based healthcare technology company that offers clinical decision support software. These programs instantly consider all relevant health information—including pharmacogenetics (PGx), comprehensive drug interactions, medical guidelines, and renal or hepatic function—to help physicians and pharmacists deliver the highest standard of evidence-based prescribing and medication reviews in a way that is tailored to their workflow. Since 2018, he has served as Specialist Medical Advisor for Babylon by TELUS Health, a healthcare mobile app that allows you to check symptoms, consult with doctors, and easily access your clinical records.
In addition to his clinical and entrepreneurial work, Prof. Dawes has a great passion for contributing to the healthcare community. He develops training programs that allow clinicians to engage in master’s level research. And when he is not at work, he enjoys spending time outdoors, fishing, and sailing.
Dan Hertz, PharmD, PhD
Assistant Professor, Department of Clinical Pharmacy, University of Michigan College of Pharmacy
Dan Hertz, PharmD, PhD
Assistant Professor, Department of Clinical Pharmacy, University of Michigan College of Pharmacy
Dr. Hertz is an assistant professor in the Department of Clinical Pharmacy at the University of Michigan College of Pharmacy. Dr. Hertz received his PharmD from Rutgers University and PhD from UNC for his dissertation research on pharmacogenetic predictors of taxane-induced neuropathy. Dr. Hertz’s current research is interested in developing tools for individualizing treatment in patients with cancer and translating them into clinical practice. He has a particular interest in optimal use of paclitaxel for women with breast cancer, including identification of an ideal exposure target to maximize efficacy while avoiding unnecessary toxicity. Dr. Hertz has several other ongoing projects to discover and translate genetic variants that affect cancer treatment outcomes, in collaborations with medical oncologists at the University of Michigan Rogel Cancer Center and within SWOG.
Terry McInnis, MD, MPH, CPE
Chief Medical Officer, Arine; President, Blue Thorn Inc. Healthcare Consulting
Terry McInnis, MD, MPH, CPE
Chief Medical Officer, Arine; President, Blue Thorn Inc. Healthcare Consulting
Currently, Dr. McInnis serves as Chief Medical Officer of Arine- an AI driven company committed to optimizing medications and improving human health through data-driven clinical services. As President and Founder of Blue Thorn Inc. healthcare consulting, Dr. McInnis has led engagements for more than 100 companies and health systems ranging from universities to analytic/diagnostic firms, health plans, provider groups, and pharmaceutical manufacturers as business models transform to succeed in an era of precision medicine and value-based care. Co-author of the article highlighting the $528 Billion US spend on non-optimized drug therapy, she is a nationally recognized expert in medication management and successful drug cost/value strategies. Her career includes a 360-degree view of healthcare including physician executive roles with GE, GSK, Michelin, and LabCorp, while steeped in consulting engagements nationally with healthcare systems and provider organizations. A physician first, she served as a USAF Flight Surgeon during Desert Shield/Storm directly supporting 38 space shuttle launches and landings- then later in civilian settings- directed occupational medicine services and led transformation efforts to risk-based care for multiple provider groups and IDNs. Currently, she works with leading-edge companies and systems committed to transforming care and optimizing medications in a financially viable, scalable, and sustainable framework.
Dr. McInnis graduated from Erskine College with a BS (summa cum laude), and received her Doctor of Medicine degree from Wake Forest Medical School being designated a NIH student clinical scholar. She completed a residency in Occupational Medicine as an OPSF scholar, and a MPH (high honors) at the University of Oklahoma. She is Board Certified in Preventive and Occupational Medicine, a Certified Physician Executive (CPE), and a Former Course Advisor to the Department of Continuing Education of Harvard University. Dr. McInnis serves as a director on the Board of Pharmacy Specialties, on the Advisory Board for Medecision, and was the Co-founder and former Board President of the Get the Medications Right Institute. She loves her dog Gingersnap, spending time in Blowing Rock, playing golf, and is active in her church.
Howard McLeod, PharmD, FASCO, FCCP
Medical Director, Precision Medicine, Geriatric Oncology Consortium; Professor, University of South Florida, College of Pharmacy
Howard McLeod, PharmD, FASCO, FCCP
Medical Director, Precision Medicine, Geriatric Oncology Consortium; Professor, University of South Florida, College of Pharmacy
Dr Howard McLeod is an internationally recognized expert in precision medicine, having made novel contributions at the discovery, translation, implementation, and policy levels. He is the Medical Director for Precision Medicine at the Geriatric Oncology Consortium and a Professor at the University of South Florida Taneja College of Pharmacy. Dr McLeod chaired the NHGRI eMERGE network external scientific panel for the past decade and was a recent member of both the FDA committee on Clinical Pharmacology and the NIH Human Genome Advisory Council. Dr McLeod has been recognized as a Fellow of both the American Society of Clinical Oncology and the American College of Clinical Pharmacy and was recently ranked #1 USA/#2 World for Pharmacogenomics. He has also been an active Board Member and/or Founder for over a dozen privately held and publicly traded companies. Howard has published over 575 peer reviewed papers on pharmacogenomics, applied therapeutics, or clinical pharmacology and continues to work to advance innovative healthcare.
Anthony P. Morreale, PharmD, MBA, BCPS, FASHP
Associate Chief Consultant, Clinical Pharmacy and Policy, Department of Veterans Affairs Pharmacy Benefits Management, VA Central Office
Anthony P. Morreale, PharmD, MBA, BCPS, FASHP
Associate Chief Consultant, Clinical Pharmacy and Policy, Department of Veterans Affairs Pharmacy Benefits Management, VA Central Office
Anthony Morreale serves as the associate chief consultant for clinical pharmacy and policy for the Department of Veterans Affairs Pharmacy Benefits Management in VA Central Office. For the past 8 years he has served as the assistant chief consultant for clinical pharmacy services and healthcare services research. Morreale has led multiple initiatives focused on organizing, standardizing and expanding the scope of clinical pharmacy practice throughout the VA. His major responsibilities are focused on identifying and resolving gaps in patient care in which clinical pharmacists have demonstrated positive outcomes and to establish new roles in complex medication management environments where clinical pharmacists can use their knowledge and training to improve patient care.
His long career as a clinical pharmacist, married with his interest in pharmacoeconomics, formulary management and clinical pharmacy health services research, resulted in the creation and implementation of numerous innovative practices for clinical pharmacists. Some of Morreale’s groundbreaking accomplishments include creating the first VA pharmacoeconics and pharmacogenomics pharmacist positions, serving as a founding member of VA’s national formulary and PBM outcomes research group, establishment of the first accredited oncology, pharmacoeconomics, pharmacogenomics, nephrology and clinical informatics residency programs in VA, and establishment of the national VA PBM Clinical Pharmacy Practice Office, which led to the development of comprehensive programs involving integration of clinical pharmacy specialists (CPS) into Patient Aligned Care Teams (PACT), mental health, pain management, antimicrobial stewardship, hepatitis C, and rural health.
Morreale is board certified in pharmacotherapy and has been the recipient of numerous professional recognitions and awards including being recognized as a Fellow of the American and California Society of Health Systems Pharmacists for his many contributions to the profession. He has also been recognized as an honorary member of the United States Public Health Service for his dedication to public health initiatives. He is a past recipient of the ASHP Best Practice Award, ASHP Literature Award for innovation, VA Under-Secretary’s Innovation Award, JMCP Quality Reviewer Award for Accuracy and Thoroughness, San Diego Society Pharmacist of the year, Pharmacy Foundation of California Michelotti Public Health Prize, and most recently the AMCP Steven G. Avey Award and the APhA Distinguished Federal Pharmacist award, which recognizes sustained, exemplary and distinguished service to the profession. Morreale has authored or co-authored more than 60 peer reviewed articles, has served on editorial boards, and as reviewer on a number of journals and has been actively involved in leadership roles within many pharmacy organizations, both nationally and internationally.
Sara Rogers, PharmD, BCPS
Director, Clinical Affairs, American Society of Pharmacovigilance
Sara Rogers, PharmD, BCPS
Director, Clinical Affairs, American Society of Pharmacovigilance
Sara Rogers is the Director of Clinical Affairs at ASP and leads the Society’s clinical, research, and educational initiatives. She also chairs the Pharmacogenomics Access and Reimbursement Coalition to address barriers to patient access and payer coverage for pharmacogenetics testing. As a clinician-scientist, Dr. Rogers conducts patient-centered research aimed at understanding the ethical and practical implications of pharmacogenomics. Prior to serving in these roles, Dr. Rogers was an Ambulatory Treatment Center Pharmacist at the University of Texas MD Anderson Cancer Center.
She received her PharmD from the University of Houston College of Pharmacy and holds a bachelor’s in from the University of Texas at Austin with a concentration in biology.
Kenneth Surprenant, MA
Patient Advocate; Retired Defense Logistics Systems Program Manager, US Department of Defense
Kenneth Surprenant, MA
Patient Advocate; Retired Defense Logistics Systems Program Manager, US Department of Defense
After the loss of his wife Kathryn due to a toxic reaction to 5FU chemotherapy in 2012, Ken has been advocating for pre-treatment identification of patients at risk of severe and life- threatening toxic reactions that may be caused with fluoropyrimidine chemotherapy. Ken’s four adult children are heterozygous DPYD carriers.
He succeeded in petitioning the US FDA to update drug product labels to more clearly identify the risk of severe toxicity (updated in 2016). Most recently, he has submitted another citizen’s petition to the FDA with the help of Drs Gabriel Brooks, Daniel Hertz, Steven Offer, and Peter O’Donnell as well as the Colorectal Cancer Alliance and another patient advocate (surviving spouse). You may read the content of the petition and offer comments at https://www.regulations.gov/docket?D=FDA-2020-P-2213 . You may also find more about this advocacy effort at www.know_the_risk_of_5fu_chemotherapy.com
Ken served over 40 years as a civilian within the US Department of Defense. He concluded his career (Jan 2017) after serving as director of 140 employees responsible for the management of development and operations of logistics information systems (Defense Logistics Agency, Information Operations, 2012-2016). Throughout his career, he demonstrated skills in project management, organization development, resource planning/execution, acquisition management and leadership development. Ken also served a six-month posting to Iraq (2010) as an advisor on logistics information systems to the US and Iraqi Army staffs. Secondary employment assignments included serving as an adjunct instructor of micro-economics at a local community college and as a high school coach of women’s soccer.
Kristin Wiisanen Weitzel, PharmD, FAPhA, FCCP
Clinical Professor, Associate Director, University of Florida Health Precision Medicine Program; Director, Graduate Program in Precision Medicine; Director, Office of Continuing Pharmacy Education
Kristin Wiisanen Weitzel, PharmD, FAPhA, FCCP
Clinical Professor, Associate Director, University of Florida Health Precision Medicine Program; Director, Graduate Program in Precision Medicine; Director, Office of Continuing Pharmacy Education
Kristin Wiisanen Weitzel is a Clinical Professor in the Department of Pharmacotherapy and Translational Research at the UF College of Pharmacy. She is the Associate Director of the UF Health Precision Medicine Program, Director of the Graduate Program in Precision Medicine, and Director of Continuing Pharmacy Education. She provides leadership in implementing clinical pharmacogenomics across diverse patient care settings in UF Health and serves as the Pharmacogenomics Residency and Fellowship Program Directors for the College of Pharmacy. Dr. Wiisanen is a fellow of the American Pharmacists Association, the American College of Clinical Pharmacy, and Editor-in-Chief of Pharmacy Today.